Administrative Core

西奈山的可用药基因组知识管理中心（KMC-IDG）将从蛋白激酶、核受体、离子通道和gpcr四个家族中收集到的可用药基因组数据进行组装、组织和可视化。KMC-IDG还将尝试将这些研究不足的可药物靶点连接起来，以用于各种疾病的潜在应用。为了实现这一目标，我们将从四个领域收集和抽象数据：蛋白质/基因/靶点，药物/扰动原，疾病/表型/副作用，以及来自个体患者的数据。将建立各种管道和工作流程，将各种疾病的患者群与尚未研究的药物靶点连接起来。Ma'ayan和Dudley实验室有能力成功地实施这个项目，因为他们之前的生产力记录、已经收集和组织的源代码基础和数据，以及强大的现有用户基础，可以引导到新开发的门户。此外，两个实验室都有很强的合作记录，包括计算鉴定和实验验证至少一种被研究的蛋白激酶作为减轻肾纤维化的潜在重要靶点。这个项目的一个独特和创新的研究组成部分是对存在于分子和细胞生物学研究领域的文献和实验偏差的来源的调查。

The Knowledge Management Center for Illuminating the Druggable Genome (KMC-IDG) at Mount Sinai will assemble, organize and visualize data collected from the under-studied druggable genome from the four families: protein kinases, nuclear receptor, ion channels and GPCRs. The KMC-IDG will also attempt linking such under-studied druggable targets for their potential applications in various diseases. To achieve this we will assemble and abstract data from four domains: proteins/genes/targets, drugs/perturbagens, diseases/phenotypes/side-effects, and data from individual patients. Various pipe-lines and workflow will be established to connect clusters of patients from various diseases to under-studied druggable targets. The Ma'ayan and Dudley Labs are well positioned to carry out successfully this project based on their prior track record of productivity, foundation of source code and data that is already collected and organized, and strong existing user base that can be directed to the newly developed portal. In addition, both labs have a strong track record of collaborations including the computational identification and experimental validation of at least one under-studied protein kinase as a potential important target for attenuating kidney fibrosis. One unique and innovative research component of this project is an investigation into the sources of the literature and experimental biases that exist in the molecular and cellular biology research domains.